Table 3.
Associations between bortezomib dosing and survival.
| Number of patients | Median (months) (95% CI) | HRa(95% CI) | p-value | |
|---|---|---|---|---|
| rwPFS | ||||
| Twice-weekly | 835 | 39.6 (33.2–46.1) | 1.00 (ref) | 0.135 |
| Once-weekly | 1457 | 37.2 (31.1–42.4) | 0.90 (0.79–1.03) | |
| rwOS | ||||
| Twice-weekly | 910 | NA (NA–NA) | 1.00 (ref) | 0.271 |
| Once-weekly | 1587 | NA (76.3–NA) | 0.90 (0.75–1.08) | |
aAdjusted for age at diagnosis, gender, race/ethnicity, practice type, ECOG PS, ISS stage, insurance, number of HRCAs, year of diagnosis, creatinine level and treatment starting route; Treatment reference group: Twice-weekly prescribing at 1L.